Trial · NCT06424834
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seattle Angina Questionnaire summary score | 5-7 weeks (depending on drug titration period) | Change in Seattle Angina Questionnaire summary score at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | EuroQol 5 dimension - 5L index score | 5-7 weeks (depending on drug titration period) | Change in EuroQol 5 dimension score - 5L index score at follow-up compared to baseline. The index ranges from -0.573 to 1.000, with a higher score indicating a better outcome. |
| Secondary | EuroQol 5 dimension - 5L visual analogue score | 5-7 weeks (depending on drug titration period) | Change in EuroQol 5 dimension score - 5L visual analogue score at follow-up compared to baseline. The index ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | PHQ-4 score | 5-7 weeks (depending on drug titration period) | Change in PHQ-4 at follow-up compared to baseline. The score ranges from 0 - 12, with a higher score indicating a worse outcome. |
| Secondary | Treatment Satisfaction Questionnaire for Medication score | 5-7 weeks (depending on drug titration period) | Change in Treatment Satisfaction Questionnaire for Medication score at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | Seattle Angina Questionnaire summary score stratified by specific chest pain endotypes | 5-7 weeks (depending on drug titration period) | Change in Seattle Angina Questionnaire summary score stratified by specific chest pain endotypes at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | EuroQol 5 dimension - 5L index score stratified by specific chest pain endotypes | 5-7 weeks (depending on drug titration period) | EuroQol 5 dimension - 5L index score stratified by specific chest pain endotypes at follow-up compared to baseline. The index ranges from -0.573 to 1.000, with a higher score indicating a better outcome. |
| Secondary | EuroQol 5 dimensions - 5L visual analogue score stratified by specific chest pain endotypes | 5-7 weeks (depending on drug titration period) | EuroQol 5 dimensions - 5L visual analogue score stratified by specific chest pain endotypes at follow-up compared to baseline. The index ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | PHQ-4 scores stratified by specific chest pain endotypes | 5-7 weeks (depending on drug titration period) | PHQ-4 score stratified by specific chest pain endotypes at follow-up compared to baseline. The score ranges from 0 - 12, with a higher score indicating a worse outcome. |
| Secondary | Treatment Satisfaction Questionnaire for Medication score stratified by specific chest pain endotypes | 5-7 weeks (depending on drug titration period) | Treatment Satisfaction Questionnaire for Medication scores stratified by specific chest pain endotypes at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | Seattle Angina Questionnaire summary score stratified by baseline angina frequency | 5-7 weeks (depending on drug titration period) | Change in Seattle Angina Questionnaire summary score stratified by baseline angina frequency at at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome. |
| Secondary | Proportion of patients with good response, no angina, and excellent health status | 5-7 weeks (depending on drug titration period) | Difference between targeted medical therapy group and placebo group in proportion of patients with good response (Seattle Angina Questionnaire summary score ≥ 10), no angina (Seattle Angina Questionnaire angina frequency score = 100), and excellent health status (Seattle Angina Questionnaire summary score ≥ 75). |
| Secondary | Safety endpoints | Baseline | Incidence of bleeding, coronary dissection, stroke, periprocedural myocardial infarction, non-self-limiting arrhythmias during the index coronary function testing procedure |
| Secondary | Major adverse cardiac events | 5-7 weeks (depending on drug titration period) | Difference between targeted medical therapy group and placebo group in incidence of cardiac death, myocardial infarction, and hospital presentation for unstable angina. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06424834/registered